Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Blood. 2021 Dec 16;138(24):2589-2592. doi: 10.1182/blood.2021012315.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chromosome Deletion
  • Chromosomes, Human, Pair 17 / genetics*
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Male
  • Middle Aged
  • Mutation / drug effects
  • Piperidines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Remission Induction
  • Rituximab / therapeutic use
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Antineoplastic Agents, Immunological
  • Piperidines
  • Protein Kinase Inhibitors
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • ibrutinib
  • Rituximab
  • Adenine